Cadrenal Therapeutics (CVKD)

• Market cap: $19.4M
• 1 day: 3.5%
• 5 days: -5.05%
• 1 month: 45.26%
• 3 months: -16.62%
• 6 months: -38.07%
• Year to date: 12.96%
• 1 year: -50.42%
• 5 years: -86.6%
• 10 years: -86.6%
• Sector: Healthcare
• Industry: Biotechnology

About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Employees: 4